Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$269M |
| 2 |
Amazon
AMZN
|
+$242M |
| 3 |
Apple
AAPL
|
+$215M |
| 4 |
Amgen
AMGN
|
+$212M |
| 5 |
Citizens Financial Group
CFG
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$210M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$195M |
| 3 |
iShares GSCI Commodity Dynamic Roll Strategy ETF
COMT
|
+$154M |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$127M |
| 5 |
WORK
Slack Technologies, Inc.
WORK
|
+$115M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.58% |
| 2 | Financials | 13.47% |
| 3 | Healthcare | 12.09% |
| 4 | Consumer Discretionary | 10.78% |
| 5 | Industrials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2826
Cue Biopharma
CUE
$131M
| $1.14M | ﹤0.01% |
2,608
-4,044
| -61% | -$1.41M |
|
2827
Radiant Logistics
RLGT
$406M
| $1.14M | ﹤0.01% |
177,788
+38,978
| +28% | +$251K |
|
2828
Harrow
HROW
$1.46B
| $1.14M | ﹤0.01% |
124,962
| – | – |
|
2829
Preformed Line Products
PLPC
$2.19B
| $1.14M | ﹤0.01% |
17,448
-9,167
| -34% | -$646K |
|
2830
Kaltura
KLTR
$243M
| $1.13M | ﹤0.01% |
+109,788
| New | +$1.3M |
|
2831
Equity Bancshares
EQBK
$1.07B
| $1.13M | ﹤0.01% |
33,776
-60,979
| -64% | -$1.91M |
|
2832
Business First Bancshares
BFST
$1.05B
| $1.13M | ﹤0.01% |
48,055
-387
| -0.8% | -$8.98K |
|
2833
Invesco Dividend Achievers ETF
PFM
$814M
| $1.12M | ﹤0.01% |
31,280
-2,837
| -8% | -$105K |
|
2834
MVB Financial
MVBF
$397M
| $1.11M | ﹤0.01% |
25,970
+1,993
| +8% | +$81.2K |
|
2835
Altimmune
ALT
$560M
| $1.11M | ﹤0.01% |
98,255
-114,295
| -54% | -$1.39M |
|
|
AUD
2836
DELISTED
Audacy, Inc.
AUD
| $1.11M | ﹤0.01% |
301,019
-518,324
| -63% | -$1.81M |
|
|
GRTS
2837
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $1.11M | ﹤0.01% |
102,370
-76,951
| -43% | -$700K |
|
2838
Avita Medical
RCEL
$248M
| $1.1M | ﹤0.01% |
62,242
+1,587
| +3% | +$29.9K |
|
|
MOFG
2839
DELISTED
MidWestOne Financial Group
MOFG
| $1.1M | ﹤0.01% |
36,466
+178
| +0.5% | +$5.2K |
|
2840
Vishay Precision Group
VPG
$908M
| $1.1M | ﹤0.01% |
31,573
-174
| -0.5% | -$6.31K |
|
2841
Karyopharm Therapeutics
KPTI
$45.1M
| $1.1M | ﹤0.01% |
12,543
-18,461
| -60% | -$1.92M |
|
2842
Aldeyra Therapeutics
ALDX
$86.9M
| $1.09M | ﹤0.01% |
124,686
-413
| -0.3% | -$3.79K |
|
2843
Teekay
TK
$1.06B
| $1.09M | ﹤0.01% |
297,299
| – | – |
|
2844
Apyx Medical
APYX
$128M
| $1.09M | ﹤0.01% |
78,415
-194
| -0.2% | -$2.04K |
|
2845
American Vanguard Corp
AVD
$62.8M
| $1.09M | ﹤0.01% |
72,187
-118,784
| -62% | -$1.88M |
|
2846
Melco Resorts & Entertainment
MLCO
$2.14B
| $1.09M | ﹤0.01% |
106,083
| – | – |
|
2847
Relmada Therapeutics
RLMD
$507M
| $1.08M | ﹤0.01% |
41,257
-57,910
| -58% | -$1.55M |
|
2848
Viking Therapeutics
VKTX
$3.84B
| $1.08M | ﹤0.01% |
172,095
+556
| +0.3% | +$3.44K |
|
|
KDNY
2849
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $1.08M | ﹤0.01% |
84,600
+4,609
| +6% | +$60.7K |
|
|
AKTS
2850
DELISTED
Akoustis Technologies Inc
AKTS
| $1.08M | ﹤0.01% |
111,011
+106
| +0.1% | +$1.02K |
|
Similar funds
Charles Schwab's Q3 2021 Portfolio in Review
As of Q3 2021, Charles Schwab held 3,610 positions worth $306B, up 1.6% from $301B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Charles Schwab's Q3 2021 filing shows 202 new, 2,185 increased, 922 reduced and 109 closed positions. Its largest new stake was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M. The largest sale was Vanguard FTSE Emerging Markets ETF, an estimated $210M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q3 2021 buy was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M.
- Charles Schwab added most to Moderna in Q3 2021, an estimated $269M increase.
- Charles Schwab's biggest Q3 2021 reduction was Vanguard FTSE Emerging Markets ETF, cutting an estimated $210M.
- Charles Schwab fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $195M.
- Charles Schwab's ten largest holdings make up 17% of its $306B portfolio in Q3 2021.
- Charles Schwab opened 202 new positions and closed 109 in Q3 2021.
- Charles Schwab's portfolio value rose 1.6% quarter-over-quarter to $306B.
Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.